Algorithms; Diabetes Mellitus, Type 2/therapy; Exercise; Family Practice; Female; Humans; Hypoglycemic Agents/therapeutic use; Male; Middle Aged; Pilot Projects
Abstract :
[en] This paper reports the results of the "DREAM" ("Diabetes REinforcement of Adequate Management") study performed among 42 general practitioners. A treatment algorithm was proposed to intensify the management of type 2 diabetic patients in case of poor control (HbA1C > 7.5% and fasting blood glucose > 140 mg/dl) before asking for an advice from a diabetologist. A total of 163 patients participated in the study: 84 men and 79 women, 59 +/- 10 years old; 5.2 +/- 6.1 years of known duration of diabetes; BMI: 30.7 +/- 5.8 kg/m2. Almost two thirds of patients received an antihypertensive agent, one third a lipid-lowering drug, and three quarters at least one antidiabetic agent: 22% a sulfonylurea, 18% metformin, 25% a combined oral therapy, 10% insulin (alone or in combination). At baseline, mean HbA1C averaged 7.1 +/- 2.2% (N: 4-6%), and 34% of patients had HbA1C > 7.5%. From these 163 patients, 100 were evaluated after 12 months, 57% being well controlled vs 36% at baseline. Among the 32 patients whose hypoglycaemic treatment was intensified, HbA1C level significantly decreased by almost 0.8% (p < 0.05). Despite precise guidelines, 55% of patients with HbA1C > 7.5% had no treatment adjustment, essentially in the group already on oral bitherapy or on insulin. Among the 65 patients evaluated after 24 months, the percentage of well controlled patients decreased to 44% (vs 51% after 12 months). The decision of switching to insulin was often delayed (no patient after 1 year and 2 patients only after 2 years). In conclusion, the "DREAM" study demonstrates the feasibility, but also the difficulty, of optimising the management of type 2 diabetic patients in general practice.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Bruwier, Geneviève ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Schmitt, H.
Language :
French
Title :
Optimalisation de la prise en charge du patient diabetique de type 2: resultats de l'etude DREAM" en medecine generale."
Alternative titles :
[en] Optimizing the management of type 2 diabetics: results of the DREAM" study in general practice"
Publication date :
2003
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Scheen AJ. - L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liège, 1999, 54, 87-94.
Zimmet PZ. - Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia, 1999, 42, 499-518.
Gandjour A, Kleinschmit F, Lauterbach KW and the INTERCARE International Investigators. - European comparison of costs and quality in the prevention of secondary complications in Type 2 diabetes mellitus (2000-2001). Diabetic Med, 2002, 19, 594-601.
Massi-Benedetti M (Ed). - The cost of diabetes type II in Europe. The CODE-2 study. Diabetologia, 2002, 45 (Suppl 1), S1-S28.
Scheen AJ, Paquot N. - Le diabète de type 2: approches diagnostiques, objectifs glycémiques et stratégies thérapeutiques. Rev Med Liège, 1999, 54, 659-666.
European Study Group. - A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group. Diabetic Med, 1999, 16, 716-730.
Leutenegger M (ed.). - Le généraliste et le diabétique non insulino-dépendant. Frison-Roche, Paris, 1995.
Le Floch JP, Thervet F, Desriac I, et al. - Management of diabetic patients by general practitioners in France 1997: an epidemiological study. Diabetes Metab, 2000, 26, 43-49.
Griffin S, Kinmonth A. - The management of diabetes by general practitioners and shared care. In: Textbook of diabetes (Pickup J, Williams G, eds), Oxford, Blackwell Scientific, 1997.
Gérard R. - Recommandations de Bonne Pratique. Diabéte de type 2. Revue Médecine Générale, 2000, 171 (suppl.), 31-58.
Scheen AJ. - Insulin therapy in the treatment of NIDDM. IDF Bulletin, 1996, 41, 16-18.
Yki-Järvinen H. - Combination therapies with insulin in type 2 diabetes. Diabetes Care, 2001, 24, 758-767.
Hermann LS. - Optiming therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging, 2000, 17, 283-294.
Ho M, Marger M, Beart J, et al. - Is the quality of diabetes care better in a diabetic clinic or in a general medicine practice? Diabetes Care, 1997, 20, 472-475.
Chwalow J, Costagliola D, Mesbah M, Eschwège E. Prise en charge du diabète de type 2 en France: attitudes et habitudes dans un échantillon représentatif de médecins généralistes. Diabetes Metab, 1995, 20, 458-464.
Detournay B, Cros S, Charbonnel B, et al. - Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab, 2000, 26, 363-369.
Griffin S. - Diabetes care in general practice: meta-analysis of randomised control trials. BMJ, 1998, 317, 390-396.
Sonnaville JJJ de, Bouma M, Colly LP, et al. - Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia, 1997, 40, 1334-1340.
Rutten GE, Maaijen J, Valkenburg AC, et al. - The Utrecht Diabetes project: telemedicine support improves GP care in Type 2 diabetes. Diabetic Med, 2001, 18, 459-463.
Varroud-Vial M, Mechaly P, Joannidis S et al. - Cooperation between general practitioners and diabetologists and clinical audit improve the management of type 2 diabetic patients. Diabetes Metab, 1999, 25, 55-63.
Scheen AJ, pour les membres du projet DREAM. Comment je traite ... Un patient diabétique de type 2: le projet "DREAM" pour une meilleure collaboration médecin généraliste - médecin spécialiste. Rev Med Liège, 1998, 53, 58-62.
Scheen AJ, Paquot N, Jandrain B. - Comment j'explore... Le risque d'un patient d'évoluer vers un diabéte de type 2. Rev Med Liège, 2002, 57, 113-115.
Scheen AJ, Lefèbvre PJ. - Oral antidiabetic agents: a guide to selection. Drugs, 1998, 55, 225-236.
Halimi S et Groupe de Travail AFSSAPS. - Traitement médicamenteux du diabète de type 2. Recommandations: texte long, argumentaire. Diabetes Metab, 1999, 25 (Suppl 6), 1-79.
Colwell JA. - DCCT findings - applicability and implications for NIDDM. Diabetes Rev, 1994, 2, 277-291.
UK Prospective Diabetes Study Group. - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
ANAES. - Suivi du patient diabétique de type 2 à l'exclusion des complications. Diabetes Metab, 1999, 25 (suppl 2), 9-13.
Detournay B, Vauzelle-Kervroedan F, Charles MA, et al. - Epidemiology, management and costs of Type 2 diabetes in France in 1998. Diabetes Metab, 1999, 25, 356-365.
Wens J, Van Casteren V, Vermeire E, et al. - Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices. Eur J Epidemiol, 2001, 17, 743-750.
Scheen AJ, Van Gaal L. - Microalbuminuria is strongly associated to indices of glycemic control and markers of insulin resistance syndrome in type 2 diabetes. Diabetes, 1998, 47, Suppl 1, A131.
Scheen AJ, Van Gaal L. - Impact of obesity on risk factors and complications in patients with type 2 diabetes: results of a large survey in general medicine practice. Int J Obesity, 1998, 22 (Suppl 3), P522.
Scheen AJ, Van Gaal L, for the OCAPI Team. - Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI survey. Diabetologia, 2002, 45 (Suppl 2), A63.
Faruqi N, Frith J, Colagiuri S, Harris M. - The use and perceived value of diabetes clinical management guidelines in general practice. Aust Fam Physician, 2000, 29, 173-176.
UK Prospective Diabetes Study Group. - Quality of life in Type 2 diabetes patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control. Diabetes Care, 1999, 22, 1125-1136.
Susman JL, Helseth LD. - Reducing the complications of type II diabetes: a patient-centered approach. Am Fam Physician, 1997, 56, 471-480.
Scheen AJ. - La non-observance thérapeutique: problème majeur pour la prévention des maladies cardiovasculaires. Rev Med Liège, 1999, 54, 914-920.
Scheen AJ. - Le médicament du mois. La rosiglitazone (Avandia®). Rev Med Liège, 2002, 57, 236-239.0
Duysinx B, Scheen AJ, Paquot N, et al. - Le diabète de Type 2 insulinorequérant: caractéristiques des patients et effets de l'insulinothérapie. Rev Med Liège, 1994, 49, 305-323.
Scheen AJ, Lefèbvre PJ. - Le diabéte non insulinodépendant: de la physiopathologie au traitement. Bull Mem Acad Roy Med Belg, 1996, 151, 395-405.
Pierce M, Agarwal G, Ridout D. - A survey of diabetes care in general practice in England and Wales. Br J Gen Pract, 2000, 50, 542-545.
Hoskins PL, Fowler PM, Constantino M, et al. - Sharing the care of diabetic patients between hospital and general practitioners: does it work? Diabetic Med, 1993, 10, 81-86.
Starfield B. - Primary care. Participants or gatekeepers? Diabetes Care, 1994, 17 (Suppl 1), 12-17.
Overland J, Mira M, Yue DK. - Diabetes management: shared care ou shared neglect. Diabetes Res Clin Pract, 1999, 44, 123-128.
Overland J, Mira M, Yue DK. - Differential shared care for diabetes: does it provide the optimal partition between primary and specialist care? Diabetic Med, 2001, 18, 554-557.
Numéro Spécial. - Epidémiologie, prise en charge et coût du diabète: les données de l'assurance maladie. Diabetes Metab, 2000, 26 (Suppl 6), 1-94.
Harris MI. - Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care, 2000, 23, 754-758.
Scheen AJ, Estrella, F. - L'étude clinique du mois. L'étude STENO-2: plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2. Rev Med Liège, 2003, 58, 109-111.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.